A phase 3 randomised open-labeled study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable or m
- Parente, Phillip (Primary Chief Investigator (PCI))
Project: Research